Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 2008 Feb;29(2):91-8. doi: 10.1016/j.tips.2007.11.005. Epub 2008 Jan 9.

Functional neuroimaging in schizophrenia: diagnosis and drug discovery.

Author information

1
Sections of Neuroimaging, Division of Psychological Medicine, Institute of Psychiatry, King's College, De Crespigny Park 16, London, UK.

Abstract

Functional neuroimaging provides a direct way of investigating the pathophysiology of schizophrenia in vivo. The function of neurotransmitters implicated in schizophrenia, such as dopamine and glutamate, can be assessed using molecular imaging techniques such as positron emission tomography (PET), single-photon emission tomography (SPET) and magnetic resonance spectroscopy (MRS). Regional brain activity, particularly that associated with the cognitive processes and symptoms associated with the disorder, can be studied using functional magnetic resonance imaging (fMRI). Here, we focus on the potential for the use of these techniques in the diagnosis of schizophrenia and in the development of new drugs for its treatment.

PMID:
18187211
DOI:
10.1016/j.tips.2007.11.005
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center